BlueCross BlueShield
Federal Employee Program

ANTIDIABETIC GLP-1, GIP-GLP-1 AGONISTS
Adlyxin injection* (lixisenatide)
Byetta injection*, Bydureon injection*, Bydureon BCise injection* (exenatide)
Mounjaro (tirzepatide)
Ozempic injection, Rybelsus tablets (semaglutide)
Trulicity injection (dulaglutide)
Victoza injection (liraglutide)

*Prior authorization for specific formulations applies only to formulary exceptions due to being a non-covered medication.

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnosis

Patient must have the following:

Type 2 diabetes mellitus

AND ALL of the following:

1. Patient must have **ONE** of the following:
    a. HbA1c ≥ 6.5%
    b. History of fasting plasma glucose (FPG) ≥ 126 mg/dL
    c. History of a 2-hour glucose of ≥ 200 mg/dL during oral glucose tolerance test (OGTT)
    d. Patient has a history of symptoms of hyperglycemia (polyuria, polydipsia, polyphagia), or hyperglycemic crisis and a random plasma glucose ≥ 200 mg/dL
2. **NO** dual therapy with other glucagon-like peptide-1 (GLP-1) receptor agonists (see Appendix 1)

Prior - Approval Limits

Quantity

Medication	Quantity Limit
Mounjaro	12 units per 84 days **OR**
Ozempic	3 units per 84 days **OR**
Rybelsus	90 tablets per 90 days **OR**
Trulicity	12 units per 84 days **OR**
Victoza	9 units per 90 days

BlueCross BlueShield
Federal Employee Program

ANTIDIABETIC GLP-1, GIP-GLP-1 AGONISTS
Adlyxin injection* (lixisenatide)
Byetta injection*, Bydureon injection*, Bydureon BCise injection* (exenatide)
Mounjaro (tirzepatide)
Ozempic injection, Rybelsus tablets (semaglutide)
Trulicity injection (dulaglutide)
Victoza injection (liraglutide)

*Prior authorization for specific formulations applies only to formulary exceptions due to being a non-covered medication.

Medication with approved formulary exception only	Quantity Limit
Adlyxin	6 units per 84 days **OR**
Bydureon/Bydureon BCise	12 units per 84 days **OR**
Byetta	3 units per 90 days **OR**

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnosis

Patient must have the following:

Type 2 diabetes mellitus

AND ALL of the following:

1. Glycemic control has improved or stabilized while on therapy
2. **NO** dual therapy with other glucagon-like peptide-1 (GLP-1) receptor agonists (see Appendix 1)

Prior - Approval *Renewal* Limits

Same as above

BlueCross BlueShield
Federal Employee Program

ANTIDIABETIC GLP-1, GIP-GLP-1 AGONISTS
Adlyxin injection* (lixisenatide)
Byetta injection*, Bydureon injection*, Bydureon BCise injection* (exenatide)
Mounjaro (tirzepatide)
Ozempic injection, Rybelsus tablets (semaglutide)
Trulicity injection (dulaglutide)
Victoza injection (liraglutide)

*Prior authorization for specific formulations applies only to formulary exceptions due to being a non-covered medication.

Appendix 1 - List of GLP-1 Agonist Medications

Generic Name	Brand Name
dulaglutide	Trulicity
exenatide	Byetta
exenatide	Bydureon, Bydureon BCise
liraglutide	Saxenda
liraglutide	Victoza
liraglutide and insulin degludec	Xultophy
lixisenatide	Adlyxin
lixisenatide and insulin glargine	Soliqua
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
tirzepatide	Mounjaro
tirzepatide	Zepbound